Innate Pharma SA: Innate Pharma Reports First Quarter 2023 Financial Results and Business Update

Exclusive worldwide rights granted to Takeda to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies; Innate to receive $5m upfront payment and eligible

Related Keywords

Chicago ,Illinois ,United States ,Rockville ,France ,French ,American ,Mondher Mahjoubi ,Henry Wheeler ,Institut Paoli Calmettes ,Arthur Rouill ,American Association For Cancer Research ,Twitter ,French Financial Markets Authority ,Euronext ,Nasdaq ,Astrazeneca ,Linkedin ,Company Annual Report On Form ,American Society For Clinical Oncology ,Exchange Commission ,Euronext Paris ,Chief Executive Officer ,Astrazeneca Trial ,Innate Pharma ,Engager Therapeutics ,Nature Biotechnology ,American Society ,Clinical Oncology ,American Association ,Cancer Research ,Antibody Drug Conjugates ,American Depositary Shares ,Private Securities Litigation Reform Act ,Risk Factors ,Universal Registration Document ,Annual Report ,Gefallene Big Techs ,Yinnate ,Dharma ,Reports ,First ,Quarter ,023 ,Financial ,Results ,Business ,Update ,